The US Pharmacopeia’s 2025 annual drug shortages report found that while the total number of shortages declined by 23% in ...
At CPHI Americas 2026, PharmTech spoke with Dr. Molly Klote, president and CEO, Klote Medical Research Advisors, and ...
CAI's Jon Thompson details how digital twins cut cleanroom commissioning time by up to 30% and accelerate GMP deviation ...
According to the USP report, the duration of drug shortages increased to 5.3 years in 2025. This is a result of new shortages ...
Clinical data warehouses maximize veracity via schema-on-write and ACID guarantees, but ETL rework, limited modality support, ...
Q5A (R2) expects sponsors to build and justify a risk-based viral safety from overlapping controls: what you prevent from ...
The EMA’s annual report shows the agency approved 104 human drugs in 2025 that included first-in-class and first-in-indication therapies. The European Medicines Agency (EMA) announced the publication ...
GSK’s $124/share all-cash offer values Nuvalent at $10.6B, targets Q3 2026 close, and is funded via new/existing debt facilities plus cash, contingent on regulatory and tender conditions. Zidesamtinib ...
The transition from a breakthrough molecule to a scalable product is the industry's greatest challenge, noted Meyer. As such, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results